Degraders of nascent proteins target N-terminal sequences (ACS-Fall 2026) - Aug 24, 2026 - Abstract #4539960; Pres time: Aug 25, 2026; 11:20 AM - 11:40 AM; Location: S105d (McCormick Place Convention Center); "The first-in-class clinical trail of KZR-261 proved safety in humans, and new companies like Gate Bioscience and Enodia Therapeutics are attracting considerable investment...A small library was designed and screened to reveal a more potent hit for PD-L1 degradation. ASERTI's model is now being used to design molecules that bind multiple residues to obtain even higher specificity for nascent protein degradation."
IO biomarker • Brain Cancer • Glioblastoma • Solid Tumor • Targeted Protein Degradation • SEC61G
|